The ASCO presentation is a non-catalyst event — mechanistic data without new efficacy endpoints or regulatory milestones. Monitor for future registrational trial updates or partnership announcements, which are the primary value drivers for ONCY. The stock has historically shown high volatility on news, but this release lacks material clinical or financial content.
Price Chart
Executive Summary
Oncolytics Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at ASCO 2026, showing pelareorep expands pre-existing tumor-reactive immune cells and activates anti-tumor responses in KRAS-mutant pancreatic cancer and early-stage breast cancer. The data are mechanistic and non-clinical, with no new efficacy results or regulatory milestones disclosed.
Key Facts
- Translational data from GOBLET (pancreatic cancer) and AWARE-1 (breast cancer) to be presented at ASCO 2026 (May 29-June 2).
- Data show pelareorep induces antiviral immune response, expands virus-specific T cells, and activates tumor-specific T cells.
- In pancreatic cancer, expansion of pre-existing TIL clones in blood correlated with reductions in tumor volume.
- T-cell receptor sequencing confirmed expansion of mutant KRAS-specific T-cell clones.
- In breast cancer biopsies, gene expression profiling showed increased antiviral/immune gene expression and CXCL13 induction linked to tertiary lymphoid structure formation.
- No new clinical efficacy data (response rates, survival) or regulatory updates were disclosed.
- Pelareorep has Fast Track designation from FDA for colorectal and pancreatic cancer.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company with $94M market cap.
Risk Factors
- Pelareorep remains investigational with no approved products; clinical trial failure risk is high.
- Company is pre-revenue and dependent on capital markets for funding; dilution risk exists.
- Translational data may not translate to clinical efficacy in registrational trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300127 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $0.7720 $0.7700 | ▼ −0.26% | ▲ +0.24% | $0.6310 (−18.26%) |
Jul 20, 2026 10w ago | 8-K | $0.8500 $0.8122 | ▼ −4.45% | ▼ −4.02% | $0.6310 (−25.76%) |
Jul 13, 2026 11w ago | 8-K | $0.9289 $0.8533 | ▼ −8.14% | ▼ −7.35% | $0.6310 (−32.07%) |
Jun 16, 2026 15w ago | 8-K | $0.9495 $0.9409 | ▼ −0.91% | ▲ +1.33% | $0.6310 (−33.54%) |
Jun 2, 2026 17w ago | 8-K | $0.9300 $0.8100 | ▼ −12.90% | ▼ −9.94% | $0.6310 (−32.15%) |
Jun 1, 2026 17w ago | 8-K | $1.06 $0.8400 | ▼ −20.75% | ▼ −18.00% | $0.6310 (−40.47%) |
May 22, 2026 19w ago | 8-K | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
May 22, 2026 19w ago | Press Release | $0.8100 $1.06 | ▲ +30.86% | ▲ +29.19% | $0.6310 (−22.10%) |
Apr 27, 2026 22w ago | 8-K | $0.9700 $0.9300 | ▼ −4.12% | ▼ −4.52% | $0.6310 (−34.95%) |
Apr 6, 2026 25w ago | 424B5 | $0.9000 $1.02 | ▼ −13.33% | ▼ −8.00% | $0.6310 (+29.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access